Incyte Reports Positive Data on Jakafi: Incyte INCY announced that the late-stage study, REACH3, evaluating Jakafi in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD) met its primary endpoint of superior overall response rate (ORR) at week 24 compared to best available therapy (BAT).The study did not achieve statistical significance on the primary endpoint, which was the 17-item Hamilton Depression Rating Scale (HAMD-17) total score change from baseline to week 5.